ArticleAmerican journal of clinical and experimental urology2025
Impact of commonly used medications on the detection of clinically significant prostate cancer in the targeted biopsy era.
Article in American journal of clinical and experimental urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare prostate cancer rates in magnetic resonance imaging (MRI)-detected lesions for patients who are chronically taking beta-blockers, nonsteroidal anti-inflammatory drugs (NSAIDs), or immunosuppressors.
methodsThis cohort consisted of 897 Prostate Imaging Reporting & Data System (PI-RADS)v2 3-5 lesions from 590 MRI-targeted fusion prostate biopsies (UroNav). Baseline characteristics and clinicopathological data were collected. A matching cohort was analyzed, and multivariate analysis was completed for each medication group. Matching analysis accounted for age, prostate-specific antigen (PSA), and PI-RADS score. Multivariate analysis additionally considered lesion size.
resultsOf the 897 lesions, 261/897 (29%) of lesions were identified as PI-RADS 3, 373/897 (42%) were PI-RADS 4, and 263/897 (29%) were PI-RADS 5. In the patient cohort, 16% were taking a beta-blocker, 3.9% were taking an NSAID, and 5.4% were taking an immunosuppressant. An equal number of lesions in controls were matched to 148 lesions in males taking beta-blockers, 37 lesions in males taking NSAIDs, and 46 lesions in males taking immunosuppressants. Matching was based on age, PSA, and PI-RADS score. In the matched cohort, neither beta-blockers, NSAIDs, nor immunosuppressants altered clinically significant prostate cancer (csPCa) identification on MRI (OR 1.11, CI 95% 0.6, 1.9; OR 0.70, CI 95% 0.32, 1.66; OR 1.73, CI 95% 0.59, 5.35, respectively).
conclusionThis pilot study shows no difference in csPCa detection rates in patients using anti-inflammatories or drugs that alter prostate blood flow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.